| The efficacy of a malarial antibody enzyme immunoassay for establishing the reinstatement status of blood donors potentially exposed to malaria. | |
| | |
MedLine Citation:
|
PMID: 15720607 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND AND OBJECTIVES: The two key objectives of the study were, first, to evaluate the sensitivity and specificity of a recombinant antigen-based malarial enzyme-linked immunoassay (EIA) and, second, to estimate the risk associated with implementing this test with a shortened cellular component restriction period (6 months rather than the standard 12-36 months) for blood donors with a malarial risk exposure. MATERIALS AND METHODS: Blood donors were recruited into four distinct groups [non-exposed (control), malarial area 'visitors', 'residents' and 'previous infection') and screened by using the Newmarket malarial antibody EIA. Assay specificity was evaluated in unexposed blood donors, and sensitivity was determined in acute clinical samples. RESULTS: No parasitaemic donors were detected amongst 337 malarial 'visitors' who had returned from a malaria-endemic area less than 6 months previously, or for 402 'visitors' or 'residents' who had returned from a malaria-endemic area more than 6 months previously. The incidence of malarial antibodies within the exposed blood donor groups was 1.33% (10/751). In acute clinical non-donor samples, the Newmarket EIA detected 106/108 (98.1; 93.5-99.5%) 'film' positive Plasmodium falciparum infections and 12/12 (100, 75.7-100.0%) P. vivax infections. The estimated additional risk exposure of the proposed new strategy was one infectious P. falciparum donation per 175 years or 1 per 4.2 years for P. vivax. CONCLUSIONS: The study findings support the efficacy and safety of a targeted screening strategy combining antibody screening with a 6-month cellular component restriction period for donors with a declared malarial risk. |
| | |
Authors:
|
C R Seed; A Cheng; T M E Davis; W V Bolton; A J Keller; A Kitchen; T J Cobain |
Related Documents
:
|
2262687 - Blood donation and risk of post-transfusion hepatitis. 23202777 - Pathologic mucosal blood vessels in active female genital schistosomiasis: new aspects ... 19774687 - Prevalence of persistent and latent viruses in untreated patients infected with hiv-1 f... 17333817 - Hepatitis b and c infection in first-time blood donors in karachi--a possible subgroup ... 21451917 - Fish bone-induced hepatic abscess: medical treatment. 3044717 - Fulminant hepatitis due to reactivation of chronic hepatitis b virus infection after al... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Vox sanguinis Volume: 88 ISSN: 0042-9007 ISO Abbreviation: Vox Sang. Publication Date: 2005 Feb |
Date Detail:
|
Created Date: 2005-02-21 Completed Date: 2005-07-21 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0413606 Medline TA: Vox Sang Country: England |
Other Details:
|
Languages: eng Pagination: 98-106 Citation Subset: IM |
Affiliation:
|
Australian Red Cross Blood Service, Perth, Australia. cseed@arcbs.redcross.org.au |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Algorithms Animals Antibodies, Protozoan / diagnostic use Blood Donors* Humans Immunoenzyme Techniques / standards* Incidence Malaria / diagnosis*, epidemiology Mass Screening / methods, standards Plasmodium falciparum / immunology* Risk Assessment Sensitivity and Specificity Time Factors |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Protozoan |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Six years' experience of using the BacT/ALERT system to screen all platelet concentrates, and additi...
Next Document: Strict red blood cell transfusion guideline reduces the need for transfusions in very-low-birthweigh...